Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim “maintaining its growth course”

Boehringer Ingelheim “maintaining its growth course”

29th July 2009

Boehringer Ingelheim is continuing to outpace the pharmaceutical market, the chairman of its board of directors has claimed.

Andreas Barner made his comments as the firm posted its financial results for the first six months of 2009.

He noted that the company has seen growth in a number of its businesses, including human pharmaceuticals and animal health.

These developments were attributed to the success of the company’s prescription medicines and vaccines.

“Local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course – virtually unchanged – and continues to outpace the pharmaceutical market,” he added.

Boehringer Ingelheim also noted that its own research and development results have been “extremely encouraging” and offer a “solid basis” for the company’s future growth.

Earlier this month, the firm announced that the European commission has approved an update on the summary of product characteristics of its Viramune (nevirapine) therapy for patients with HIV.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.